Skip to content

Aspen Gets Unsolicited Offers for Pharma Ingredient Unit

  • Africa’s largest drugmaker already sold other chemical assets
  • Aspen will start a process of evaluating acquisition proposals
Aspen Pharmacare Holdings Ltd Chief Executive Officer Stephen Saad Interview
Photographer: Waldo Swiegers/Bloomberg
Updated on

Aspen Pharmacare Holdings Ltd. has received two unsolicited offers for its active pharmaceutical ingredient business and will start a process aimed at evaluating proposals for the unit.

The approaches are for operations almost exclusively in Europe and make both chemicals and the anticoagulant drug heparin, Chief Executive Officer Stephen Saad said by phone Thursday. The company has has already sold most of its other heparin interests, part of a recent slimming down effort to reduce debt.